Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q06323

UPID:
PSME1_HUMAN

ALTERNATIVE NAMES:
11S regulator complex subunit alpha; Activator of multicatalytic protease subunit 1; Interferon gamma up-regulated I-5111 protein; Proteasome activator 28 subunit alpha

ALTERNATIVE UPACC:
Q06323; A6NJG9; H0YNE3; Q6IBM2; Q9UEF4

BACKGROUND:
The protein known as Proteasome activator complex subunit 1, with alternative names such as Activator of multicatalytic protease subunit 1, plays a crucial role in the immunoproteasome assembly, essential for the efficient processing of antigens. This protein's function in the PA28 activator complex significantly influences the generation of peptides that bind to class I molecules, altering the proteasome's cleavage pattern.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Proteasome activator complex subunit 1 offers a promising pathway to developing novel therapeutic approaches. Its critical role in enhancing antigen processing highlights its potential as a therapeutic target in managing diseases related to immune system dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.